Last reviewed · How we verify

Plain bupivacaine

Fayoum University Hospital · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local infiltration anesthesia, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic namePlain bupivacaine
Also known asBupivacaine Hydrochloride
SponsorFayoum University Hospital
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that reversibly binds to and inactivates voltage-gated sodium channels on the inner surface of nerve cell membranes. This prevents depolarization and the generation of action potentials, thereby blocking nerve conduction in a dose-dependent manner. The drug is commonly used for infiltration anesthesia, nerve blocks, and epidural/spinal anesthesia due to its prolonged duration of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: